Genmab A/S is a Denmark-headquartered biotechnology company listed on NasdaqGS in the Pharmaceutical Preparations sector, focused on therapeutic biologics development and commercialization. The name trades in a market where clinical outcomes and sentiment drive large price moves, so share-price action and institutional behavior are important signals for investors tracking the therapeutic theme.
Price action has been constructive: the last close was $35.32 (as of 2026-09-25), trading above the 50-day average ($32.01) and the 200-day average ($29.53). The stock has significantly outperformed the S&P 500 over the last three months (excess return +29.4%) and modestly over 12 months (+3.3%). Institutional holding is meaningful at roughly 17.0% reported as of 2026-06-30 across 381 institutions, with the average top holder increasing position size materially and about two-thirds of top holders showing position increases. Volume measures also favor accumulation, with a 50-day up/down volume ratio of 1.61 and an accumulation score near the top of the scale.
Those market signals place Genmab in a favorable position within the Biotech Therapeutics theme: strong short-term relative strength, widespread institutional sponsorship, and limited distribution concerns make the stock a timely leader for trend-following and thematic screens. The technical picture is constructive but not flawless, so the name is more a leading candidate to watch than one with a fresh, verified breakout.
Why now
Shares sit within a confirmed uptrend and are roughly flat to their 52-week high, backed by a pronounced three-month outperformance versus the S&P 500 and clear institutional accumulation; this combination puts Genmab at the center of attention for investors tracking high-momentum therapeutics names, while the setup still lacks a validated breakout or short-term add trigger.
The setup
Technically, last close $35.32 is above the 9-day and 21-day EMAs ($34.64 and $33.93), the 50-day SMA ($32.01) and the 200-day SMA ($29.53); distance to the 9-day EMA is about 1.97% and to the 21-day EMA about 4.08%. Momentum measures are firm (14-day RSI ~65.7) and six of seven trend checks are positive, but a longer-term moving-average condition did not verify and the long average has stopped rising, a topping characteristic. Entry-readiness is flagged as watch, not actionable, because no fresh breakout or verified 9/21-day EMA add setup is present.
Revenue trajectory
Quarterly revenue with year-over-year growth. Solid bars are actuals from SEC EDGAR filings (XBRL); dashed bars are analyst consensus via Yahoo Finance (19 analysts).Earnings trajectory
Solid bars are quarterly GAAP diluted EPS from SEC EDGAR filings. Dashed bars are analyst consensus, which is typically adjusted (non-GAAP). The two are measured differently, so a step between the last actual and the first estimate usually reflects that change in basis rather than a change in the business.Analyst full-year EPS consensus (typically adjusted): FY'26E $1.13 (-36%) · FY'27E $1.59 (+41%) — 19 analysts
Risks
Price vulnerability from a technical topping pattern is the primary risk: the long average has stopped rising, so a failed push above the 52-week range could prompt a pullback. Biotech-sector sensitivity to clinical or regulatory news means sentiment-driven volatility can erase recent gains quickly. Finally, while institutional ownership is significant, concentrated selling by large holders or a rotation out of therapeutics names would pressure the stock despite the current accumulation signals.
Framework fit
Minervini Trend Template
6/7Stage 2 confirmation checklist: price versus rising long-term moving averages and the 52-week range.
Weinstein Stage
Price is near or above the 30-week proxy, but the long average has stopped rising.